Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE: MAIA) has announced a private placement offering of 463,332 shares of common stock at $1.50 per share to accredited investors and a Company director. The offering includes warrants to purchase an equal number of shares at $1.71 per exercise price, exercisable after six months with a five-year term. The private placement is expected to close around May 29, 2025, with anticipated gross proceeds of approximately $695,000.
The company plans to use the proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act.
MAIA Biotechnology (NYSE: MAIA) announced the acceptance of their abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase efficacy data from their Phase 2 THIO-101 clinical trial of ateganosine (THIO), a telomere targeting agent, in combination with cemiplimab for third-line immune checkpoint inhibitor-resistant advanced NSCLC.
The poster, titled "Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC: Evaluation of Overall Survival," will be presented by Dr. Tomasz Jankowski on May 31, 2025, from 1:30 PM to 4:30 PM CDT in the Lung Cancer track. CEO Vlad Vitoc expressed confidence in ateganosine's potential to become a best-in-class anticancer treatment.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. The offering includes warrants to purchase one share of common stock at $2.05 per share, exercisable one year after issuance with a six-year term.
The private placement is expected to close around May 7, 2025. The proceeds will be used to fund the initiation of Part C of the Phase II THIO-101 trial and for working capital. Securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the Company's 2021 Equity Incentive Plan.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.05, exercisable after six months with a five-year term. The placement is expected to close around May 7, 2025.
The company plans to use the proceeds to fund the initiation of Part C of their Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the company's 2021 Equity Incentive Plan.